Improvement of renal oxidative stress markers after ozone administration in diabetic nephropathy in rats

Diabetology and Metabolic Syndrome

Volumn 2, Issue 1, 2010, Pages

  Morsy, Mohamed D ^a   Hassan, Waleed N ^a   Zalat, Sherif I ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; ANTIOXIDANT; BIOLOGICAL MARKER; CATALASE; CREATININE; GLYCOSYLATED HEMOGLOBIN; INSULIN; MALONALDEHYDE; OZONE; STREPTOZOCIN; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; HEMOGLOBIN BLOOD LEVEL; KIDNEY PARENCHYMA; MALE; NONHUMAN; OXIDATIVE STRESS; OZONE THERAPY; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL;

EID: 79959685286     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-2-29     Document Type: Article

References (51)

1. Preventing or slowing the progression of diabetic nephropathy. Greald B, Appel MD, BUMC Proceedings 1999 12 6
2. Mass-screening for early detection of renal disease-benefits and limitations of self-testing for proteinuria. Heidland A, Bahner U, Deetjen A, Götz R, Heidbreder E, Schäfer R, Teschner M, J Nephrol 2009 22 2 249 54 19384843
3. Elevated serum C-reactive protein level and microalbuminuria in patients with type 2 diabetes mellitus. Mojahedi MJ, Bonakdaran S, Hami M, Sheikhian MR, Shakeri MT, Aiatollahi H, Iran J Kidney Dis 2009 3 1 12 6 19377253
4. Cellular basis of diabetic nephropathy: Study design and renal structural- functional relationships in patients with long-standing type 1 diabetes. Caramori ML, Kim Y, Huang C, Fish AJ, Rich SS, Miller ME, Russel G, Mauer M, Diabetes 2002 51 506 13 10.2337/diabetes.51.2.506 11812762 (Pubitemid 34764810)
5. Urinary oidative stress markers closely reflect the efficacy of Candesartan treatment for diabetic nephropathy. Yoshida SI, Hashimoto T, Kihara M, Imai N, Nomura K, Hirawa N, Toya Y, Kitamura H, Umemura S, Nephron Exp Nephrol 2008 111 20 30 10.1159/000178764
6. Evaluation of renal gene expression of protein kinase C isoforms in diabetic and nondiabetic proliferative glomerular diseases. Ibrahim S, Rashed L, Fadda S, Scientific World J 2008 31 835 44
7. Inhibition of advanced glycation end products. an implicit goal for the treatment of diabetic nephropathy. Miyata T, Dan T, Diabetes Res Clin Pract 2008 13 82 6
8. Diabetic nephropathy: where hemodynamics meets metabolism. Forbes JM, Fukami K, Cooper MF, Exp Clin Endocrinol Diabetes 2007 115 69 84 10.1055/s-2007-949721 17318765 (Pubitemid 46408113)
9. Effect of aminoguadin on erythrocyte lipid peroxidation and activities of antioxidant enzymes in experimental diabetes. Kedziora-Kornatowska KZ, Luciak M, Blaszczyk Y, Pawlak W, Clin Chem Lab Med 1998 36 771 5 10.1515/CCLM.1998.137 9853804 (Pubitemid 28521530)
10. Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney. Ha H, Lee H, Nephrology 2005 10 7 10 10.1111/j.1440-1797.2005.00448.x 15705174 (Pubitemid 41743468)
11. Decrease of blood cholesterol and stimulation of antioxidative response on cardiopathy patients treated with endovenous ozone therapy. Hernandez F, Menendez S, Wong R, Free Rad Biol Med 1995 19 115 9 10.1016/0891-5849(94)00201-T 7635353
12. Preconditioning with ozone/oxygen mixture induces reversion of some indicators of oxidative stress and prevents organic damage in rats with fecal peritonitis. Rodriguez ZZ, Guanche D, Alvarez RG, Rosales FH, Alonso Y, Schulz S, Inflamm Res 2009 19274439
13. Influence of ozone on haemoglobin oxygen affinity in type-2 diabetic patients with peripheral vascular disease: in vitro studies. Coppola L, Giunta R, Verrazzo G, Luongo C, Sammartino A, Vicario C, Giugliano D, Diabetes Metab 1995 21 252 5
14. Ozone oxidative preconditioning protects the rat kidney from reperfusion injury: the role of nitric oxide. Chen H, Xing B, Liu X, Zhang B, Zhou J, Zhu H, Chen Z, J Surg Res 2008 149 287 95 10.1016/j.jss.2007.12.756 18262565
15. Prevention of renal injury after induction of ozone tolerance in rats submitted to warm ischaemia. Barber E, Menendez S, Leon OS, Barber MO, Merino N, Calunga JL, Cruz E, Bocci V, Mediators Inflamm 1999 8 37 41 10.1080/09629359990702 10704088 (Pubitemid 29195655)
16. A study on the relationship between homocysteine and diabetic nephropathy in rats. Unlucerci Y, Bekpinar S, Gurdol F, Seferoglu G, Pharmacol Res 2002 45 3 249 52 10.1006/phrs.2001.0942 11884223 (Pubitemid 35428789)
17. Effect of aminoguadin on erythrocyte lipid peroxidation and activities of antioxidant enzymes in experimental diabetes. Kedziora-Kornatowska KZ, Luciak M, Blaszczyk Y, Pawlak W, Clin Chem Lab Med 1998 36 771 5 10.1515/CCLM.1998.137 9853804 (Pubitemid 28521530)
18. Tissue-specific transcriptome responses in rats with early streptozotocin-induced diabetes. Knoll KE, Pietrusz JL, Liang M, Physiol Genomics 2005 21 222 9 10.1152/physiolgenomics.00231.2004 15713786 (Pubitemid 40898482)
19. Coordinated patterns of gene expression for substrate and energy metabolism in skeletal muscle of diabetic mice. Yechoor VK, Patti ME, Saccone R, Kahn CR, Proc Natl Acad Sci USA 2002 99 10587 92 10.1073/pnas.142301999 12149437
20. Effect of ozone treatment on ROS and adenosine production during hepatic ischemia-reperfusion. Peralta C, Xaus C, Bartrons R, Leon OS, Gelpi E, Rosello-Catafau J, Free Radic Res 2000 33 595 605 10.1080/10715760000301121 11200091 (Pubitemid 32103700)
21. Direct gene delivery of human tissue kallikrein reduces blood pressure in SHR. Wang C, Chao L, Chao J, J Clin Invist 1995 95 1710 1716 10.1172/JCI117847
22. Review of Medical Physiology. Ganong W, London UK. Appelton and Lang Co 19 1999 573 581
23. Effects of Vanadate on renal hypertrophy and sorbitol accumulation in streptozotocin induced diabetes in rats. James W, Martha L, Mary A, James M, Margaret A, Gali R, Res Com-mun Pathol Pharmacol 1991 72 2 180 89
24. Direct enzymatic determination of urea in the plasma and urine with a centrifugal analyzer. Bretaudiere JP, Phung HT, Baily M, Clinical Chemistry 1976 22 1614 7 975505
25. Analytical reviews in clinical biochemistry: the estimation of creatinine. Spencer K, Ann Clin Biochem 1986 23 1 25 3532908 (Pubitemid 16178799)
26. Determination of blood glucose using 4-amino phenazone as oxygen acceptor. Trinder P, J Clin Pathol 1969 22 2 246 10.1136/jcp.22.2.246-b 5776563
27. A new colorimetric method for the estimation of glycosylated hemoglobin. Nayak SS, Pattabiraman TN, Clin Chem Acta 1981 109 267 74 10.1016/0009-8981(81) 90312-0 (Pubitemid 11165574)
28. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Ohkawa H, Ohishi N, Yagi K, Anal Biochem 1979 95 351 8 10.1016/0003-2697(79)90738-3 36810 (Pubitemid 9194347)
29. The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen. Nishikimi M, Rao NA, Yagi K, Biochem Biophys Res Commun 1972 46 849 54 10.1016/S0006-291X(72)80218-3 4400444
30. A modified spectrophotometric assay of superoxide dismutase. Kakkar P, Das B, Viswanathan PN, Indian J Biochem Biophys 1984 21 130 2 6490072 (Pubitemid 15207169)
31. Human erythrocyte catalase: an improved method of isolation and revaluation of reported properties. Bonaventura J, Schroeder WA, Fang S, Arch Biochem Biophys 1972 150 606 17 10.1016/0003-9861(72)90080-X 5044042
32. Studies on quantitative and qualitative characterization of erythrocyte GPx. Pagalia DE, Valentine WN, The Journal of Laboratory and Clinical Medicine 1967 70 158 6066618
33. Purification and characterization of the recombinant human aldose reductase expressed in baculovirus system. Nishimura C, Yamaoka T, Mizutani M, Yamashita K, Akera T, Tanimoto T, Biochim Biophys Acta 1991 1078 171 8 1905957
34. Microvascular and Macrovascular Complications of Diabetes. Michael J, Fowler MD, Clinical Diabetes 2008 26 77 82 10.2337/diaclin.26.2.77 (Pubitemid 351556223)
35. Role of oxidative stress in development of cardiovascular complications in diabetes mellitus. Haidara M, Yassin H, Rateb M, Ammar H, Zorkani M, Current Vascular Pharmacology 2006 4 215 27 10.2174/157016106777698469 16842139 (Pubitemid 46785489)
36. Experimental diabetic nephropathy can be prevented by propolis: Effect on metabolic disturbances and renal oxidative parameters. Abo-Salem OM, El-Edel RH, Harisa GE, El-Halawany N, Ghonaim MM, Pak J Pharm Sci 2009 22 2 205 10 19339234
37. Brain and liver mitochondria isolated from diabetic rats show different susceptibility to induced oxidative stress. Santo MS, Santos DL, Diabet Metab Res Rev 2001 17 223 30 10.1002/dmrr.200 (Pubitemid 32624605)
38. Micronutrients as nutriceutical interventions in diabetes mellitus. Cunningham JJ, J Am Coll Nutr 1998 17 7 12 9477383
39. Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: one year observational follow-up study. Yang Y, He X, Chen S, Wang L, Li E, Xu L, Endocrine 2009 36 1 45 5 10.1007/s12020-009-9187-x 19390997
40. Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat. Toba H, Sawai N, Morishita M, Murata S, Yoshida M, Nakashima K, Morita Y, Kobara M, Nakata T, Eur J Pharmacol 2009 612 1-3 106 14 10.1016/j.ejphar.2009. 03.065 19356735
41. Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. Soto C, Recoba R, Barron H, Alvarez C, Favari L, Comp Biochem Physiol C Toxicol Pharmacol 2003 136 205 12 10.1016/S1532-0456(03)00214-X 14659454 (Pubitemid 37500850)
42. 2: Activation of the EGF receptor/ERK pathway. Hassan WN, Cantuti-Castelevetri I, Denisova N, Yee AS, Joseph JA, Paulson KE, Free Rad Biol Med 2002 32 551 61 10.1016/S0891-5849(02)00744-X 11958956 (Pubitemid 34215040)
43. Ozone treatment reduces markers of oxidative and endothelial damage in an experimental diabetes model in rats. Al-Dalain SM, Martínez G, Candelario-Jalil E, Pharmacol Res 2001 44 391 6 10.1006/phrs.2001.0867 11712870 (Pubitemid 33105079)
44. Oxidative preconditioning affords protection against carbon tetrachloride-induced glycogen depletion and oxidative stress in rats. Candelario-Jalil E, Al-Dalain SM, Leán OS, J Appl Toxicol 2001 21 297 301 10.1002/jat.758 11481663 (Pubitemid 32755701)
45. Altered endothelial NO synthase targeting and conformation and Caveolin-1 expression in the diabetic kidney. Radko K, William ES, John FR, Jessie NL, Terry TO, David CB, Scott LM, Sharon A, Diabetes 2006 55 1651 9 10.2337/db05-1595 16731827 (Pubitemid 44324117)
46. 3influx. Di Baccio D, Castagna A, Paoletti E, Sebastiani L, Ranieri A, Tree Physiol 2008 28 12 1761 72 19193559
47. Therapeutic efficacy of ozone in patients with diabetic foot. Martínez G, Al-Dalain SM, Menéndez S, Giuliani A, Alvarez H, Fernández JI, Leán OS, Eur J Pharmacol 2005 31 151 61 10.1016/j.ejphar.2005.08.020 (Pubitemid 41562387)
48. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nishikawa T, Edelstein D, Du XL, Nature 2000 404 787 90 10.1038/35008121 10783895 (Pubitemid 30212409)
49. Antidiabetic and antioxidant activity of Annona squamosa extract in STZ-induced diabetic rats. Kaleem M, Asif M, Ahmed QU, Bano B, Singapore Med J 2006 47 670 8 16865205
50. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Cardillo C, Nambi SS, Kilcovne CM, Choucair WK, Katz A, Quon MJ, Panza JA, Circulation 1999 100 820 5 10458717 (Pubitemid 29398879)
51. Improvement of the mitochondrial antioxidant defense status prevents cytokine-induced nuclear factor-kappa B activation in insulin-producing cells. Azevedo-Martins AK, Lortz S, Lenzen S, Curi R, Eizirik DL, Tiedge M, Diabetes 2003 52 1 93 101 10.2337/diabetes.52.1.93 12502498 (Pubitemid 36042112)